150 related articles for article (PubMed ID: 8621251)
1. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
2. Absence of frameshift mutations in the bax gene in renal cell cancer (RCC) and transitional cell cancer (TCC).
Bilim VN; Kawasaki T; Takahashi K; Tomita Y
Anticancer Res; 1998; 18(3A):1655-9. PubMed ID: 9673385
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
4. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
5. Infrequent alteration of p53 pathway in metastatic renal cell carcinoma.
Kawasaki T; Bilim V; Takahashi K; Tomita Y
Oncol Rep; 1999; 6(2):329-33. PubMed ID: 10022999
[TBL] [Abstract][Full Text] [Related]
6. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
7. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
Hirata H; Hinoda Y; Nakajima K; Kawamoto K; Kikuno N; Ueno K; Yamamura S; Zaman MS; Khatri G; Chen Y; Saini S; Majid S; Deng G; Ishii N; Dahiya R
Int J Cancer; 2011 Apr; 128(8):1793-803. PubMed ID: 20549706
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
9. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
Oudard S; Levalois C; Andrieu JM; Bougaran J; Validire P; Thiounn N; Poupon MF; Fourme E; Chevillard S
Anticancer Res; 2002; 22(1A):121-8. PubMed ID: 12017273
[TBL] [Abstract][Full Text] [Related]
10. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia.
Furihata M; Sonobe H; Ohtsuki Y; Yamashita M; Morioka M; Yamamoto A; Terao N; Kuwahara M; Fujisaki N
J Pathol; 1996 Feb; 178(2):133-9. PubMed ID: 8683378
[TBL] [Abstract][Full Text] [Related]
11. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
12. p53 and HER-2 alterations in renal cell carcinoma.
Zhang XH; Takenaka I; Sato C; Sakamoto H
Urology; 1997 Oct; 50(4):636-42. PubMed ID: 9338750
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.
Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
Neoplasia; 2014 Dec; 16(12):1028-35. PubMed ID: 25499216
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 oncoprotein in renal cell tumours.
Paraf F; Gogusev J; Chrétien Y; Droz D
J Pathol; 1995 Nov; 177(3):247-52. PubMed ID: 8551386
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
[TBL] [Abstract][Full Text] [Related]
16. Human gliomas with wild-type p53 express bcl-2.
Alderson LM; Castleberg RL; Harsh GR; Louis DN; Henson JW
Cancer Res; 1995 Mar; 55(5):999-1001. PubMed ID: 7867012
[TBL] [Abstract][Full Text] [Related]
17. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour.
Contractor H; Zariwala M; Bugert P; Zeisler J; Kovacs G
J Pathol; 1997 Feb; 181(2):136-9. PubMed ID: 9120715
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
19. Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas.
Pepe S; Ruggiero A; D'Acquisto M; De Laurentiis M; De Placido S; Sandomenico C; Staibano S; De Rosa G; Lucariello A; D'Armiento M; Bianco AR
Cancer; 2000 Sep; 89(5):1065-75. PubMed ID: 10964337
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
